STAT+: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Glenmark Pharmaceuticals agreed to pay $29.6 million to settle allegations from dozens of states that it participated in a widespread conspiracy to artificially inflate and manipulate prices of generic medicines, harming consumers by reducing competition.
- Dozens of state attorneys general accused Glenmark of price-fixing in a coordinated campaign against major generic manufacturers, alleging the scheme reduced competition across the sector.
- The settlement is the latest in a decade-long legal battle that previously drew collective settlements of $67 million from Lannett, Bausch, Apotex, and Heritage Pharmaceuticals.
- The litigation was launched roughly 10 years ago amid heightened concern over prescription drug costs, including for generics — drugs that account for approximately 90% of all prescriptions written in the U.S. each year.
Why it matters: Combined with the $67 million already extracted from Lannett, Bausch, Apotex, and Heritage, Glenmark's $29.6 million payment brings total recoveries in this decade-long state-led generics price-fixing case to roughly $96.6 million — a concrete price tag for conduct that allegedly touched medicines filling about 90% of U.S. prescriptions.
